This abstract illustrates how remote patient monitoring with the RESP® Biosensor can be applied in infectious and cardiopulmonary diseases to detect early pulmonary involvement and guide intervention. The cases are drawn from observational studies in three distinct patient groups: hospitalized patients with asthma, COPD, or COVID-19; patients hospitalized for acute heart failure; and healthy adults at risk for respiratory infections.

In one COPD case, lung sounds increased by 119% from baseline prior to discharge, with readmission occurring five days later. In a heart failure case, progressive rales were detected without a change in respiratory rate, preceding a hospital readmission and eventual death. In the infectious disease cohort, 11 participants had coughs captured by the RESP Biosensor but did not self-report cough.

Together, these cases show how continuous lung sound monitoring may provide more actionable insights than self-reported symptoms alone, offering a telehealth solution for early detection of exacerbations, prevention of costly readmissions, and improved infectious disease surveillance.